Literature DB >> 25242770

Survival benefit of transplantation for recurrence of hepatocellular carcinoma after liver resection.

F Tuci1, A Vitale2, F D'Amico3, E Gringeri1, D Neri1, G Zanus1, D Bassi1, M Polacco1, R Boetto1, E Lodo1, G Germani4, P Burra4, P Angeli3, U Cillo1.   

Abstract

BACKGROUND: Liver transplantation (LT) for hepatocellular carcinoma (HCC) can be used for tumor recurrence after liver resection (LR) both for initially transplant-eligible patients as conventional salvage therapy (ST) and for non-transplant-eligible patients (beyond Milan criteria) with a goal of downstaging (DW). The aim of this study was to compare the intention-to-treat (ITT) survival rates of patients who are listed for LT, according to these two strategies.
METHODS: We analyzed a prospective database of 399 consecutive patients who underwent hepatic resection for HCC from 2002 to 2011 to identify patients included in the waiting list for tumor recurrence. Intention-to-treat (ITT) survivals were compared with those of patients resected for HCC within and beyond Milan criteria in the same period and not included in the LT waiting list.
RESULTS: The study group consisted of 42 patients, 28 in the ST group (within Milan) and 14 in the DW group (beyond Milan). The 5-year ITT survival rate was similar between the 2 groups, being 64% for ST and 60% for DW (P=.84). Twenty-five patients (15 ST and 10 DW) underwent LT, 13 (10 ST and 3 DW) were still awaiting LT, 4 (3 ST and 1 DW) dropped out of the waiting list because of tumor progression, and 7 (5 ST [33%] and 2 DW [20%]) had tumor recurrence. The 5-year ITT survival of ST patients was similar to that of 252 in-Milan HCC patients resected only (P=.3), whereas 5-year ITT survival of DW patients was significantly higher (P<.01) than that of 105 beyond-Milan HCC patients resected only.
CONCLUSIONS: LR seems to be a safe and effective therapy both as alternative to transplantation and as downstaging strategy for intermediate-advanced HCC. The survival benefit of salvage LT, however, seems to be higher in the 2nd than in the 1st group.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25242770     DOI: 10.1016/j.transproceed.2014.07.031

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

Review 1.  Liver resection for intermediate hepatocellular carcinoma.

Authors:  Peng-Sheng Yi; Ming Zhang; Ji-Tong Zhao; Ming-Qing Xu
Journal:  World J Hepatol       Date:  2016-05-18

Review 2.  Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.

Authors:  Po-Chih Yang; Cheng-Maw Ho; Rey-Heng Hu; Ming-Chih Ho; Yao-Ming Wu; Po-Huang Lee
Journal:  World J Hepatol       Date:  2016-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.